Compass Therapeutics Inc

NASDAQ:CMPX  
2.59
+0.16 (+6.65%)
Products

Compass Therapeutics Reports Positive Interim Phase 2 Data Of Ctx-009

Published: 05/04/2022 13:41 GMT
Compass Therapeutics Inc (CMPX) - Compass Therapeutics Reports Positive Interim Phase 2 Data of Ctx-009 in Combination With Paclitaxel in Biliary Tract Cancers.compass Therapeutics Inc. - Ctx-009 Demonstrated a 42% Overall Response Rate (orr) Based on 10 Partial Responses (prs) in 24 Enrolled Patients.compass Therapeutics Inc. - Ctx-009 Continues to Be Well Tolerated, Consistent With Phase 1 Studies.compass Therapeutics Inc. - Compass Plans to Initiate Stage 2 of Phase 2 Study in U.S. in Q3 2022.